Last reviewed · How we verify

NCT05046340: AFRIC

Applicability of Fluid Responsiveness Indices in Circulatory Failure (AFRIC Study) Study Project

Status unknown Last updated 14 February 2023
What this trial tests

trial testing Passive leg raising in Shock in 200 participants. Status unknown.

Timeline
10 January 2019
Primary endpoint
28 February 2023
31 December 2023

Quick facts

Lead sponsorBicetre Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date10 January 2019
Primary completion28 February 2023
Estimated completion31 December 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Bicetre Hospital

Who can join

18 and older, any sex, with Shock or Acute Circulatory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fluid administration is one of the main strategies for patients with acute circulatory failure. However, about half of the patients could not benefit from the fluid administration after the ICU admission. Thus predict the effect of fluid responsiveness is essential. There are sevral indices or tests can be used, such as pulse pressure variation (PPV), end-expiratory occulsion test (EEOT), passive leg raising (PLR), etc. Question of the prevalence of cases in which the different predictive indices of fluid responsiveness in intensive care unit (ICU) are not applicable.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Passive leg raising

Trials testing the same drug.

Other recruiting trials for Shock

Currently open trials in the same condition.

Other Bicetre Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05046340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing